LUCA MOLOGNI
机构: University of Milano-Bicocca
每年引用次数
引用次数
引用: 6,869
H-指数: 43
I10-指数 : 74
出版物: 164
Abstract #4418: Dissection of the RET/beta-catenin interaction in the thyroid cancer line TPC1
Luca Mologni , Carlo Gambacorti-Passerini , Carla Donadoni , Elisa Manieri
Cancer Research 69 4418 -4418
2009
Dissection of the RET/β-catenin interaction in the TPC1 thyroid cancer cell line.
Luca Mologni , Carlo Gambacorti-Passerini , Carla Donadoni , Elisa Manieri
American Journal of Cancer Research 1 ( 6) 716 -725
13
2011
The Myopathic Protein Myotilin in Developing Mouse and in Muscle Function
Luca Mologni
Helsingin yliopisto
1
2009
Expanding the portfolio of anti-ALK weapons.
Luca Mologni
Translational lung cancer research 4 ( 1) 5 -7
5
2015
Inhibition of Promyelocytic Leukemia (PML)/Retinoic Acid Receptor-α and PML Expression in Acute Promyelocytic Leukemia Cells by Anti-PML Peptide Nucleic Acid
Luca Mologni , Carlo Gambacorti-Passerini , Edoardo Marchesi , Peter E. Nielsen
Cancer Research 61 ( 14) 5468 -5473
39
2001
Pharmaceutical combinations for the treatment of cancer
Luca Mologni , Carlo Gambacorti
3
2009
Resistance mechanisms to ALK TKIs in tumors other than lung cancer
Luca Mologni
Academic Press 101 -121
2021
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Elena Ardini , Maria Menichincheri , Patrizia Banfi , Roberta Bosotti
Molecular Cancer Therapeutics 15 ( 4) 628 -639
133
2016
Sorafenib Functions to Potently Suppress RET Tyrosine Kinase Activity by Direct Enzymatic Inhibition and Promoting RET Lysosomal Degradation Independent of Proteasomal Targeting
Iván Plaza-Menacho , Luca Mologni , Elisa Sala , Carlo Gambacorti-Passerini
Journal of Biological Chemistry 282 ( 40) 29230 -29240
76
2007
Inhibition of RET tyrosine kinase by SU5416.
Luca Mologni , Elisa Sala , Sara Cazzaniga , Roberta Rostagno
Journal of Molecular Endocrinology 37 ( 2) 199 -212
63
2006
Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors
Claudia Voena , Matteo Menotti , Cristina Mastini , Filomena Di Giacomo
Cancer immunology research 3 ( 12) 1333 -1343
23
2015
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors.
Sébastien Tardy , Alexandre Orsato , Luca Mologni , William H. Bisson
Bioorganic & Medicinal Chemistry 22 ( 4) 1303 -1312
14
2014
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.
Philipp le Coutre , Elena Tassi , Marileila Varella-Garcia , Rossella Barni
Blood 95 ( 5) 1758 -1766
692
2000
The Novel Synthetic Retinoid 6-(3-adamantyl-4-hydroxyphenyl)-2-naphthalene Carboxylic Acid (CD437) Causes Apoptosis in Acute Promyelocytic Leukemia Cells Through Rapid Activation of Caspases
Luca Mologni , Isabella Ponzanelli , Filippo Bresciani , Gabriele Sardiello
Blood 93 ( 3) 1045 -1061
82
1999
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer
Elisa Sala , Luca Mologni , Sara Cazzaniga , Elena Papinutto
International Journal of Biological Macromolecules 39 ( 1-3) 60 -65
3
2006
Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold
Wiebke Brandt , Luca Mologni , Lutz Preu , Thomas Lemcke
European Journal of Medicinal Chemistry 45 ( 7) 2919 -2927
37
2010
ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells
Vera Magistroni , Luca Mologni , Stefano Sanselicio , James Frances Reid
PLoS ONE 6 ( 11) e28162
23
2011
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
Luca Mologni , Sara Redaelli , Andrea Morandi , Ivan Plaza-Menacho
Molecular and Cellular Endocrinology 377 ( 1) 1 -6
71
2013
Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Sara Redaelli , Luca Mologni , Roberta Rostagno , Rocco Piazza
American Journal of Hematology 87 ( 11)
114
2012
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy
Elisa Bossi , Andrea Aroldi , Filippo A. Brioschi , Carolina Steidl
American Journal of Hematology 95 ( 12)
2
2020